Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Majaliwa Mzombwe

Pain Medicine Eugene, OR Medical Doctor

NPI 1447813738 CMS profile 11527215

217 Division Ave, Eugene, OR 97404

Open in the dashboard

General payments

$6,805

119 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Majaliwa Mzombwe of Eugene, OR is reported in the CMS Open Payments database as having received $6,805 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,468 33
2024 General $3,834 55
2023 General $1,503 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Majaliwa Mzombwe
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Majaliwa Mzombwe were reported at $1,468. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Majaliwa Mzombwe Pain Medicine median Middle half National median
2019 $0 $506 $144–$1,566 $163
2020 $0 $315 $96–$934 $114
2021 $0 $452 $134–$1,237 $132
2022 $0 $475 $124–$1,407 $149
2023 $1,503 $480 $136–$1,384 $160
2024 $3,834 $521 $164–$1,511 $164
2025 $1,468 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Medtronic, Inc. $2,604 41 payments
  2. Boston Scientific Corporation $1,672 22 payments
  3. Spinal Simplicity, LLC $792 16 payments
  4. BIOTRONIK NRO, Inc. $519 10 payments
  5. Abbott Laboratories $322 11 payments
  6. Foundation Fusion Solutions, LLC $243 3 payments
  7. MML US, Inc. $212 4 payments
  8. Saluda Medical Americas, Inc. $96 2 payments
  9. Stryker Corporation $73 1 payment
  10. SPR Therapeutics, Inc $66 1 payment
  11. Other $207 8 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,868 100 payments
  2. Travel and Lodging $2,938 19 payments
Products named General payments · program years 2023–2025
  1. VANTA ADAPTIVESTIM $1,160 19 payments
  2. KYPHON EXPRESS II KYPHOPAK TRAY $1,142 10 payments
  3. HA MINUTEMAN G3-R $792 16 payments
  4. Prospera $519 10 payments
  5. ReActiv8 $212 4 payments
  6. WaveWriter Alpha Prime 16 $192 4 payments
  7. Intracept $184 3 payments
  8. INTELLIS ADAPTIVESTIM $160 11 payments
  9. ETERNA $147 6 payments
  10. Accurian $142 1 payment
  11. Other $958 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

273

Median for Pain Management: 951

Drug cost

$3,947

Median for Pain Management: $26,034

Branded share of claims

28.9%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Calcitonin-Salmon Calcitonin,salmon,synthetic Brand 20 $1,353
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 59 $775
Methylprednisolone Generic 88 $695
Buprenorphine Hcl Generic 12 $409
Oxycodone Hcl Generic 22 $318
Gabapentin Generic 20 $219
Meloxicam Generic 41 $142
Tramadol Hcl Generic 11 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$58,743

Of which drugs: $138

Medicare patients

224

Average age 73

Services billed

1,959

153 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Depression 31%
Diabetes 26%
Osteoporosis 23%
Chronic kidney disease 21%
Ischemic heart disease 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 30 1,281 $129

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record